Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2017

  • ID: 4311885
  • Report
  • 123 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • AstraZeneca Plc
  • CTI BioPharma Corp
  • Genentech Inc
  • Japan Tobacco Inc
  • Novartis AG
  • MORE
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary:

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 2, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Myeloproliferative Disorders, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atopic Dermatitis, Myelofibrosis, Asthma, Auto Inflammatory Disease, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Leukemias, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Astrocytoma, B-Cell Leukemia, Cancer Anorexia-Cachexia Syndrome, Chronic Lymphocytic Leukemia (CLL), Dermatitis, Dermatomyositis, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Essential Thrombocythemia, Giant Cell Arteritis, Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoma, Multiple Sclerosis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Proliferative Diabetic Retinopathy (PDR), Psoriatic Arthritis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Failure, Respiratory Tract Inflammatory Disorders, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Thalassemia, Thrombocythemia Myelofibrosis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • AstraZeneca Plc
  • CTI BioPharma Corp
  • Genentech Inc
  • Japan Tobacco Inc
  • Novartis AG
  • MORE
  1. Introduction
  2. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview
  3. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  14. Aerie Pharmaceuticals Inc
  15. Aptose Biosciences Inc
  16. AstraZeneca Plc
  17. Bristol-Myers Squibb Company
  18. Celon Pharma SA
  19. CTI BioPharma Corp
  20. Eli Lilly and Company
  21. Genentech Inc
  22. Incyte Corp
  23. Japan Tobacco Inc
  24. Nerviano Medical Sciences Srl
  25. Nippon Shinyaku Co Ltd
  26. Novartis AG
  27. Simcere Pharmaceutical Group
  28. Theravance Biopharma Inc
  29. Tragara Pharmaceuticals Inc
  30. Vectura Group Plc
  31. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles
  32. AR-13154 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. AZD-1480 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. baricitinib - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. BVB-808 - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. CHZ-868 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. CPL-407105 - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. Drugs to Inhibit JAK2 for Rheumatoid Arthritis - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. JTE-052 - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. MA-2014 - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. NMSP-113 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. NMSP-953 - Drug Profile
  73. Product Description
  74. Mechanism Of Action
  75. R&D Progress
  76. NS-018 - Drug Profile
  77. Product Description
  78. Mechanism Of Action
  79. R&D Progress
  80. pacritinib - Drug Profile
  81. Product Description
  82. Mechanism Of Action
  83. R&D Progress
  84. ruxolitinib phosphate - Drug Profile
  85. Product Description
  86. Mechanism Of Action
  87. R&D Progress
  88. SAR-317461 - Drug Profile
  89. Product Description
  90. Mechanism Of Action
  91. R&D Progress
  92. Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile
  93. Product Description
  94. Mechanism Of Action
  95. R&D Progress
  96. Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile
  97. Product Description
  98. Mechanism Of Action
  99. R&D Progress
  100. Small Molecules to Inhibit JAK2 for Cancer - Drug Profile
  101. Product Description
  102. Mechanism Of Action
  103. R&D Progress
  104. Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
  105. Product Description
  106. Mechanism Of Action
  107. R&D Progress
  108. Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile
  109. Product Description
  110. Mechanism Of Action
  111. R&D Progress
  112. TD-1473 - Drug Profile
  113. Product Description
  114. Mechanism Of Action
  115. R&D Progress
  116. TD-3504 - Drug Profile
  117. Product Description
  118. Mechanism Of Action
  119. R&D Progress
  120. TG-02 - Drug Profile
  121. Product Description
  122. Mechanism Of Action
  123. R&D Progress
  124. VR-588 - Drug Profile
  125. Product Description
  126. Mechanism Of Action
  127. R&D Progress
  128. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
  129. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
  130. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
  131. Featured News & Press Releases
  132. Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib
  133. Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders
  134. Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)
  135. Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  136. Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
  137. Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis
  138. Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
  139. Jan 13, 2017: U.S. FDA Extends Review Period For Baricitinib, An Investigational Rheumatoid Arthritis Treatment
  140. Jan 09, 2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For
  141. Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
  142. Dec 30, 2016: Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
  143. Dec 16, 2016: CHMP Recommends Approval of Lillys Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)
  144. Dec 06, 2016: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting
  145. Dec 04, 2016: Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib)
  146. Nov 21, 2016: CTI BioPharma Announces data on Pacritinib at ASH Annual Meeting
  147. Appendix
  148. Methodology
  149. Coverage
  150. Secondary Research
  151. Primary Research
  152. Expert Panel Validation
  153. Contact Us
  154. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Products under Development by Companies, H1 2017 (Contd..4), H1
  12. Number of Products under Investigation by Universities/Institutes, H1
  13. Products under Investigation by Universities/Institutes, H1
  14. Number of Products by Stage and Mechanism of Actions, H1
  15. Number of Products by Stage and Route of Administration, H1
  16. Number of Products by Stage and Molecule Type, H1
  17. Pipeline by Aerie Pharmaceuticals Inc, H1
  18. Pipeline by Aptose Biosciences Inc, H1
  19. Pipeline by AstraZeneca Plc, H1
  20. Pipeline by Bristol-Myers Squibb Company, H1
  21. Pipeline by Celon Pharma SA, H1
  22. Pipeline by CTI BioPharma Corp, H1
  23. Pipeline by Eli Lilly and Company, H1
  24. Pipeline by Genentech Inc, H1
  25. Pipeline by Incyte Corp, H1
  26. Pipeline by Japan Tobacco Inc, H1
  27. Pipeline by Nerviano Medical Sciences Srl, H1
  28. Pipeline by Nippon Shinyaku Co Ltd, H1
  29. Pipeline by Novartis AG, H1
  30. Pipeline by Simcere Pharmaceutical Group, H1
  31. Pipeline by Theravance Biopharma Inc, H1
  32. Pipeline by Tragara Pharmaceuticals Inc, H1
  33. Pipeline by Vectura Group Plc, H1
  34. Dormant Products, H1
  35. Dormant Products, H1 2017 (Contd..1), H1
  36. Dormant Products, H1 2017 (Contd..2), H1
  37. Dormant Products, H1 2017 (Contd..3), H1
  38. Discontinued Products, H1
  39. Discontinued Products, H1 2017 (Contd..1), H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aerie Pharmaceuticals Inc
  • Aptose Biosciences Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Celon Pharma SA
  • CTI BioPharma Corp
  • Eli Lilly and Company
  • Genentech Inc
  • Incyte Corp
  • Japan Tobacco Inc
  • Nerviano Medical Sciences Srl
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Tragara Pharmaceuticals Inc
  • Vectura Group Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll